UpdatesPress Release
Biocon announced pivotal clinical data publications reinforcing its Yesafili™ (Eylea® biosimilar) effectiveness and equivalence.
Biocon LimitedBIOCON · Filed with the exchange
This milestone strengthens its upcoming U.S. launch, expanding patient access and positioning the company for significant market penetration.
No comments yet. Be the first.